{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:48:59Z","timestamp":1793911739548,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Convocat\u00f2ria d\u2019Intensificaci\u00f3 Interna per als professionals de l\u2019HCB 2023 Emili-Letang"},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/01660"],"award-info":[{"award-number":["PI22\/01660"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/01660"],"award-info":[{"award-number":["PI22\/01660"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML) remain therapeutic challenges with suboptimal outcomes. The only potentially curative treatment is allogeneic stem cell transplantation (allo-SCT). The most frequent pre-allo-SCT treatment is monotherapy with hypomethylating agents (HMA), but approximately 40% of patients cannot proceed to allo-SCT, mainly due to disease progression. Recent evidence suggests that combining HMA with venetoclax (HMA\/VEN) could increase HMA efficacy in HR-MDS but it remains unclear if this combination could bridge more patients to allo-SCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively evaluated HMA\/VEN as a bridge to allo-SCT in 30 patients with HR-MDS or CMML eligible for transplant. Eighteen patients were treatment-na\u00efve and 12 were refractory or relapsed (R\/R).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>As defined by the IWG 2023 criteria, the overall response rate (ORR) was 90% and the composite complete response rate was 77%. For the R\/R patients, ORR was 83%. The allo-SCT rate was 83%, and the allo-SCT rate of those patients treated exclusively with HMA\/VEN without further bridge therapies was 76%. One- and two-year post-allo-SCT survival was 75% and two-year cumulative incidence of relapse was 30.5%. Follow-up of measurable residual disease identified some molecular relapses that were controlled with preemptive treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings indicate that HMA\/VEN combination therapy shows promise as a bridging strategy to allo-SCT in HR-MDS and CMML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40164-025-00652-5","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T01:32:45Z","timestamp":1745631165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study"],"prefix":"10.1186","volume":"14","author":[{"given":"Ines","family":"Zugasti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Lopez-Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Casta\u00f1o-D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Avenda\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Pomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Garc\u00eda-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Padilla","family":"Conejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"de la Fuente Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Mart\u00ednez-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Merch\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Jim\u00e9nez-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Guijarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Ram\u00f3n","family":"\u00c1lamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Cortes-Bullich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Torrecillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Mont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Carcelero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Riu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lurdes","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bargay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Triguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Suarez-Lled\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Queralt","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"L\u00f3pez-Cadenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Xicoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Valc\u00e1rcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Arnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Fern\u00e1ndez-Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"D\u00edez-Campelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"D\u00edaz-Bey\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"issue":"30","key":"652_CR1","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1200\/JCO.20.03380","volume":"39","author":"R Nakamura","year":"2021","unstructured":"Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50\u201375 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39(30):3328\u201339.","journal-title":"J Clin Oncol"},{"issue":"7","key":"652_CR2","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1182\/blood-2016-02-700054","volume":"128","author":"M Pfeilstocker","year":"2016","unstructured":"Pfeilstocker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Sole F, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128(7):902\u201310.","journal-title":"Blood"},{"issue":"7","key":"652_CR3","doi-asserted-by":"publisher","first-page":"EVIDoa200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1(7):EVIDoa200008.","journal-title":"NEJM Evid"},{"issue":"30","key":"652_CR4","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1200\/JCO.20.02724","volume":"39","author":"N Kroger","year":"2021","unstructured":"Kroger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, et al. Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced mds according to donor availability (VidazaAllo Study). J Clin Oncol. 2021;39(30):3318\u201327.","journal-title":"J Clin Oncol"},{"issue":"28","key":"652_CR5","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1200\/JCO.23.00866","volume":"41","author":"J Versluis","year":"2023","unstructured":"Versluis J, Saber W, Tsai HK, Gibson CJ, Dillon LW, Mishra A, et al. Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the blood and marrow transplant clinical trials network 1102 study. J Clin Oncol. 2023;41(28):4497\u2013510.","journal-title":"J Clin Oncol"},{"issue":"4","key":"652_CR6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","volume":"8","author":"JS Garcia","year":"2024","unstructured":"Garcia JS, Kim HT, Murdock HM, Ansuinelli M, Brock J, Cutler CS, et al. Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 2024;8(4):978\u201390.","journal-title":"Blood Adv"},{"issue":"3","key":"652_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/leu.2011.234","volume":"26","author":"U Platzbecker","year":"2012","unstructured":"Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012;26(3):381\u20139.","journal-title":"Leukemia"},{"issue":"4","key":"652_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/jamaoncol.2019.5140","volume":"6","author":"E Atallah","year":"2020","unstructured":"Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, et al. Comparison of patient age groups in transplantation for myelodysplastic syndrome: the medicare coverage with evidence development study. JAMA Oncol. 2020;6(4):486\u201393.","journal-title":"JAMA Oncol"},{"issue":"11","key":"652_CR9","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1182\/blood.2024025464","volume":"145","author":"JS Garcia","year":"2024","unstructured":"Garcia JS, Platzbecker U, Odenike O, Fleming SA, Yew Fong C, et al. Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2024;145(11):1126\u201335.","journal-title":"Blood"},{"issue":"13","key":"652_CR10","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","volume":"129","author":"T de Witte","year":"2017","unstructured":"de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129(13):1753\u201362.","journal-title":"Blood"},{"issue":"3","key":"652_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223\u201332.","journal-title":"Lancet Oncol"},{"issue":"20","key":"652_CR12","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1200\/JCO.2012.44.6823","volume":"31","author":"G Garcia-Manero","year":"2013","unstructured":"Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, et al. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013;31(20):2548\u201353.","journal-title":"J Clin Oncol"},{"issue":"8","key":"652_CR13","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794\u2013803.","journal-title":"Cancer"},{"key":"652_CR14","doi-asserted-by":"publisher","first-page":"100791","DOI":"10.1016\/j.blre.2020.100791","volume":"48","author":"C Saygin","year":"2021","unstructured":"Saygin C, Carraway HE. Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021;48:100791.","journal-title":"Blood Rev"},{"issue":"7","key":"652_CR15","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41409-023-01970-0","volume":"58","author":"A Baranwal","year":"2023","unstructured":"Baranwal A, Chhetri R, Yeung D, Clark M, Shah S, Litzow MR, et al. Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study. Bone Marrow Transplant. 2023;58(7):769\u201376.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"652_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jtct.2022.11.014","volume":"29","author":"Z DeFilipp","year":"2023","unstructured":"DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, et al. Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American society for transplantation and cellular therapy committee on practice guidelines. Transplant Cell Ther. 2023;29(2):71\u201381.","journal-title":"Transplant Cell Ther"},{"key":"652_CR17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fonc.2018.00636","volume":"8","author":"CM Adams","year":"2018","unstructured":"Adams CM, Clark-Garvey S, Porcu P, Eischen CM. Targeting the Bcl-2 family in B cell lymphoma. Front Oncol. 2018;8:636.","journal-title":"Front Oncol"},{"issue":"3","key":"652_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41591-022-01696-4","volume":"28","author":"I Ganan-Gomez","year":"2022","unstructured":"Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, et al. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med. 2022;28(3):557\u201367.","journal-title":"Nat Med"},{"issue":"7","key":"652_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"key":"652_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1182\/blood-2020-139492","volume":"136","author":"JS Garcia","year":"2020","unstructured":"Garcia JS, Wei AH, Borate U, Fong CY, Baer MR, Nolte F, et al. Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study. Blood. 2020;136:55\u20137.","journal-title":"Blood"},{"issue":"2","key":"652_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/ajh.26771","volume":"98","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Borate U, Pollyea DA, Brunner AM, Roncolato F, Garcia JS, et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol. 2023;98(2):272\u201381.","journal-title":"Am J Hematol"},{"issue":"11","key":"652_CR22","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1080\/10428194.2022.2084730","volume":"63","author":"R Khanam","year":"2022","unstructured":"Khanam R, Shahzad M, Chaudhary SG, Ali F, Shah Z, Pachika PS, et al. Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis. Leuk Lymphoma. 2022;63(11):2671\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"652_CR23","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1158\/1078-0432.CCR-23-0842","volume":"29","author":"D Levitz","year":"2023","unstructured":"Levitz D, Saunthararajah Y, Fedorov K, Shapiro LC, Mantzaris I, Shastri A, et al. A metabolically optimized, noncytotoxic low-dose weekly decitabine\/venetoclax in MDS and AML. Clin Cancer Res. 2023;29(15):2774\u201380.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"652_CR24","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1182\/bloodadvances.2023010113","volume":"7","author":"R Masetti","year":"2023","unstructured":"Masetti R, Baccelli F, Leardini D, Gottardi F, Vendemini F, di Gangi A, et al. Venetoclax-based therapies in pediatric advanced MDS and relapsed\/refractory AML: a multicenter retrospective analysis. Blood Adv. 2023;7(16):4366\u201370.","journal-title":"Blood Adv"},{"key":"652_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00216-2","author":"A Bazinet","year":"2022","unstructured":"Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, et al. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1\u20132 study. Lancet Haematol. 2022. https:\/\/doi.org\/10.1016\/S2352-3026(22)00216-2.","journal-title":"Lancet Haematol"},{"issue":"24","key":"652_CR26","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","volume":"29","author":"T Prebet","year":"2011","unstructured":"Prebet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322\u20137.","journal-title":"J Clin Oncol"},{"issue":"13","key":"652_CR27","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","volume":"4","author":"BJ Ball","year":"2020","unstructured":"Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M, et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020;4(13):2866\u201370.","journal-title":"Blood Adv"},{"issue":"3","key":"652_CR28","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(23)00367-8","volume":"11","author":"A Bataller","year":"2024","unstructured":"Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, et al. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1\/2 study. Lancet Haematol. 2024;11(3):e186\u201395.","journal-title":"Lancet Haematol"},{"issue":"5","key":"652_CR29","doi-asserted-by":"publisher","first-page":"E185","DOI":"10.1002\/ajh.26504","volume":"97","author":"S Ball","year":"2022","unstructured":"Ball S, Jain AG, Aguirre LE, Al Ali N, Zhang Y, Chan O, et al. Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: is the combination indeed better? Am J Hematol. 2022;97(5):E185\u20138.","journal-title":"Am J Hematol"},{"issue":"5","key":"652_CR30","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s41375-021-01240-2","volume":"35","author":"G Montalban-Bravo","year":"2021","unstructured":"Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, et al. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021;35(5):1494\u20139.","journal-title":"Leukemia"},{"issue":"11","key":"652_CR31","doi-asserted-by":"publisher","first-page":"E433","DOI":"10.1002\/ajh.26334","volume":"96","author":"AN Saliba","year":"2021","unstructured":"Saliba AN, Litzow MR, Gangat N, Al-Kali A, Foran JM, Hogan WJ, et al. Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. Am J Hematol. 2021;96(11):E433\u20136.","journal-title":"Am J Hematol"},{"issue":"11","key":"652_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41408-022-00744-z","volume":"12","author":"RS Komrokji","year":"2022","unstructured":"Komrokji RS, Singh AM, Ali NA, Chan O, Padron E, Sweet K, et al. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome. Blood Cancer J. 2022;12(11):148.","journal-title":"Blood Cancer J"},{"issue":"6","key":"652_CR33","doi-asserted-by":"publisher","first-page":"E214","DOI":"10.1002\/ajh.26539","volume":"97","author":"N Gangat","year":"2022","unstructured":"Gangat N, McCullough K, Johnson I, Al-Kali A, Begna KH, Patnaik MM, et al. Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. Am J Hematol. 2022;97(6):E214\u20136.","journal-title":"Am J Hematol"},{"issue":"3","key":"652_CR34","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/hon.3112","volume":"41","author":"C Mei","year":"2023","unstructured":"Mei C, Ye L, Ren Y, Zhou X, Ma L, Xu G, et al. 15-days duration of venetoclax combined with azacitidine in the treatment of relapsed\/refractory high-risk myelodysplastic syndromes: a retrospective single-center study. Hematol Oncol. 2023;41(3):546\u201354.","journal-title":"Hematol Oncol"},{"issue":"12","key":"652_CR35","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1007\/s00277-022-04983-9","volume":"101","author":"TT Yang","year":"2022","unstructured":"Yang TT, Song XL, Zhao YM, Ye BD, Luo Y, Xiao HW, et al. Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients. Ann Hematol. 2022;101(12):2731\u201341.","journal-title":"Ann Hematol"},{"issue":"17","key":"652_CR36","first-page":"2047","volume":"141","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Ades L, Borate U, et al. Consensus proposal for revised international working group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 2023;141(17):2047\u201361.","journal-title":"Blood"},{"issue":"12","key":"652_CR37","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","volume":"125","author":"MR Savona","year":"2015","unstructured":"Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, et al. An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults. Blood. 2015;125(12):1857\u201365.","journal-title":"Blood"},{"issue":"2","key":"652_CR38","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419\u201325.","journal-title":"Blood"},{"issue":"12","key":"652_CR39","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"5","key":"652_CR40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000516655","volume":"161","author":"J McGowan-Jordan","year":"2021","unstructured":"McGowan-Jordan J, Hastings R, Moore S. Re: international system for human cytogenetic or cytogenomic nomenclature (ISCN): some thoughts, by T. Liehr. Cytogenet Genome Res. 2021;161(5):225\u20136.","journal-title":"Cytogenet Genome Res"},{"issue":"6","key":"652_CR41","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","volume":"20","author":"P Gorello","year":"2006","unstructured":"Gorello P, Cazzaniga G, Alberti F, Dell\u2019Oro MG, Gottardi E, Specchia G, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006;20(6):1103\u20138.","journal-title":"Leukemia"},{"issue":"8","key":"652_CR42","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","volume":"57","author":"JA Snowden","year":"2022","unstructured":"Snowden JA, Sanchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022;57(8):1217\u201339.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"652_CR43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389\u2013401.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"652_CR44","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22(1):4\u201310.","journal-title":"Biol Blood Marrow Transplant"},{"key":"652_CR45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145613","author":"JS Garcia","year":"2021","unstructured":"Garcia JS, Wei AH, Jacoby MA, Fong CY, Borate U, Baer MR, et al. Molecular responses are observed across mutational spectrum in treatment-na\u00efve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine. Blood. 2021. https:\/\/doi.org\/10.1182\/blood-2021-145613.","journal-title":"Blood"},{"key":"652_CR46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189446","author":"JS Garcia","year":"2023","unstructured":"Garcia JS, Platzbecker U, Odenike O, Fleming S, Fong CY, Cook R, et al. Efficacy and safety of venetoclax in combination with azacitidine for the treatment of patients with treatment-naive higher-risk myelodysplastic syndromes. Blood. 2023. https:\/\/doi.org\/10.1182\/blood-2023-189446.","journal-title":"Blood"},{"key":"652_CR47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187102","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G, Odenike O, Fleming S, Roboz GJ, Jacoby M, Cunningham I, et al. Combination of venetoclax and azacitidine in patients with treatment-naive, high-risk myelodysplastic syndromes with responses leading to stem cell transplantation. Blood. 2023. https:\/\/doi.org\/10.1182\/blood-2023-187102.","journal-title":"Blood"},{"issue":"9","key":"652_CR48","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41409-023-02027-y","volume":"58","author":"E Maffini","year":"2023","unstructured":"Maffini E, Ngoya M, Galimard JE, Harbi S, Kroger N, Platzbecker U, et al. Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia working party of the European society for blood and marrow transplantation (EBMT). Bone Marrow Transplant. 2023;58(9):1033\u201341.","journal-title":"Bone Marrow Transplant"},{"key":"652_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.leukres.2016.12.001","volume":"53","author":"AD Heini","year":"2017","unstructured":"Heini AD, Berger MD, Seipel K, Taleghani BM, Baerlocher GM, Leibundgut K, et al. Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years. Leuk Res. 2017;53:28\u201334.","journal-title":"Leuk Res"},{"issue":"7","key":"652_CR50","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/annonc\/mdx154","volume":"28","author":"MT Voso","year":"2017","unstructured":"Voso MT, Leone G, Piciocchi A, Fianchi L, Santarone S, Candoni A, et al. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Ann Oncol. 2017;28(7):1547\u201353.","journal-title":"Ann Oncol"},{"issue":"7","key":"652_CR51","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.bbmt.2017.03.020","volume":"23","author":"BM Getta","year":"2017","unstructured":"Getta BM, Kishtagari A, Hilden P, Tallman MS, Maloy M, Gonzales P, et al. Allogeneic hematopoietic stem cell transplantation is underutilized in older patients with myelodysplastic syndromes. Biol Blood Marrow Transplant. 2017;23(7):1078\u201386.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"652_CR52","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1002\/cncr.25247","volume":"116","author":"E Jabbour","year":"2010","unstructured":"Jabbour E, Garcia-Manero G, Batty N, Shan J, O\u2019Brien S, Cortes J, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116(16):3830\u20134.","journal-title":"Cancer"},{"issue":"8","key":"652_CR53","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/ajh.26984","volume":"98","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(8):1307\u201325.","journal-title":"Am J Hematol"},{"issue":"6","key":"652_CR54","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/bjh.16206","volume":"189","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Ades L. How we manage adults with myelodysplastic syndrome. Br J Haematol. 2020;189(6):1016\u201327.","journal-title":"Br J Haematol"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00652-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00652-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00652-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T03:02:26Z","timestamp":1745636546000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00652-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["652"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00652-5","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interests. JE: consultancy-honoraria (Abbvie, Novartis, Astellas, Jazz Pharmaceuticals, BMS-Celgene, Pfizer, Daiichi-Sankyo), research grants (Novartis, Jazz Pharmaceuticals); MD-B.: consultant or advisory role, travel grants or speaker (Bristol Myers Squibb-Celgene, Abbvie, Astellas, JazzPharma, Takeda, Novartis). SC-D: travel grants from Novartis, Abbie, Jazz Pharmaceuticals. IZ: Travel grant from Jazz Pharmaceuticals. For the remaining authors, no conflicts of interest were declared. These organizations had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}